NEUP

Neuphoria Therapeutics Inc. (NEUP) | Rumor.io

Neuphoria Therapeutics

NEUP

Attention (50-day avg)0%

Attention rank (50-day avg)#4,337

Bullish sentiment (50-day avg)0%

Price to earnings ratio1.07

Market capitalization19.8M

Earnings per share-3.06

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about NEUP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% +0

Jul 23

Neuphoria Therapeutics Inc. (NEUP) and Scancell Holdings plc (SCLP) have announced an all-share merger, where Scancell will acquire Neuphoria.
The combined company will operate as Scancell, advancing a pipeline of targeted, off-the-shelf, active immunotherapies, with Scancell shareholders owning approximately 85.5% and Neuphoria holders owning around 14.5%.
The deal comes with up to $89M in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+, and Neuphoria's shareholders may receive CVRs (convertible notes) in addition to the merger consideration.

Generated by AI

Sentiment

Of the messages about NEUP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0%	71.14% -14.25
Bearish	—	100%	100%	28.86% +14.25

Bullish· Oct 27

The company is likely to be sold, with a potential price range of $15 or higher, and a possible leak of takeover talks within 24 hours.
The company has taken measures to prevent a hostile takeover, including capping the current 37% holder and implementing poison pills, which could lead to a buyout.
The stock is expected to quadruple in value, with some investors already making significant profits, and the company's filing has confirmed the validity of bullish predictions.

Bearish· Oct 24

$NEUP's bid sizes significantly outweigh ask sizes, indicating a strong selling trend.
The company's recent $15M funding round may be a trap, as insiders are unlikely to sell shares and instead bought from the market.
$NEUP's price has dropped significantly from its daily highs, with a 6.30 average price point being a concerning level.

Generated by AI

Topics

Of the messages about NEUP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	13.84%
Technical Analysis	—	—	—	24.13%
Analysts	—	—	—	30.57%
Controversies	—	—	—	0.2%
Earnings	—	—	—	0%
Macro	—	—	—	31.25%

Jul 23

Scancell Holdings plc and Neuphoria Therapeutics Inc. have announced an all-share merger, with Scancell acquiring Neuphoria in an all-share transaction, and the combined company to operate under the name Scancell.
The merger deal includes up to $89 million in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+, and the combined company plans to apply for listing on the Nasdaq under the symbol "SCLT".
Under the terms of the merger, each outstanding share of Neuphoria common stock will be converted into 37.77199 Scancell American Depositary Shares (ADSs) and one Contingent Value Right (CVR), with Scancell shareholders owning approximately 85.5% of the combined entity.

Generated by AI

Community

Of the messages about NEUP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	50%	8.33%
Newcomers	—	100%	50%	91.67%

Regulars· Jul 23

The merger deal between Neuphoria Therapeutics Inc. and Scancell is expected to result in a post-dilution valuation of $239M, with Neuphoria receiving approximately 10% of the combined entity.
The current market capitalization of Scancell is estimated to be around $150M, and the pre-money valuation is around $160M, with Neuphoria's share valued at $4.30-4.40 per share.
The CVRs (contingent value rights) associated with the merger are expected to be worth a significant amount, with some estimates suggesting a value of $13 per share for Neuphoria, implying a total value of $511M for the combined entity.

Newcomers· Jul 23

The merger between Neuphoria Therapeutics Inc. ($NEUP) and Scancell Holdings plc ($SCLP) is an all-share transaction, with Scancell shareholders owning 85.5% of the combined entity.
The deal includes up to $89M in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+, which will be the combined company's lead program.
The merger is expected to result in a significant increase in Neuphoria's share price, with some investors anticipating a target price of $4.00 or higher.

Generated by AI

News

Neuphoria Therapeutics to Merge with Scancell Holdings

Detailed price information for Neuphoria Therapeutics Inc (NEUP-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing

Scancell Holdings (LSE:SCLP) has agreed to merge with U. S.

2mo agoYahoo Finance UK

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

2mo agoMorningstar

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

All-share transaction creating a combined company to operate as Scancell advancing a pipeline of targeted, off-the-shelf, active immunotherapiesCombined...

2mo agoBarchart.com

Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

Neuphoria Therapeutics (NEUP) and Scancell Holdings said Thursday they have agreed to an all-stock m

2mo agoYahoo Finance

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the Oxford-based cancer immunotherapy developer listed on London's junior AIM market, has agreed an all-share merger with US biotech Neuphoria Therapeutics that will give it a Nasdaq listing and access to American investors. The combined...

2mo agoYahoo Finance

Also Discussed

Investors talking about NEUP also mention

#	Name	Attention
1	Processa Pharmaceuticals Inc.PCSA	0%0
2	BNOX - Bionomics Limited	——
3	enGene Therapeutics Inc.ENGN	0%0
4	Vsee Health Inc.VSEE	0%0
5	Scienture Holdings, Inc.SCNX	0%0
6	Inhibrx Biosciences, Inc.INBX	0%0
7	BeneficientBENF	0.01%0
8	TCTM - TCTM Kids IT Education Inc.	——
9	Insight Acquisition Corp.AMOD	0%0
10	Spruce Biosciences, Inc.SPRB	0%0

Neuphoria Therapeutics Inc.

Healthcare
Biotechnology

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric and central nervous system disorders. The company’s current pipeline centers on BNC210, an oral drug candidate being developed for social anxiety disorder and post-traumatic stress disorder, with a mechanism designed to selectively modulate the a7 nicotinic acetylcholine receptor. Neuphoria Therapeutics also works on other preclinical and clinical programs in neuroscience and oncology, reflecting a research-driven portfolio that spans multiple therapeutic areas. Headquartered in Burlington, Massachusetts, with operations connected to Australia, the company contributes to the broader biopharmaceutical market by advancing drug candidates aimed at complex neurological and psychiatric conditions.

Website

Location

14 Milliston Road

Millis, MA, 02054

United States

Social

What share of all stock conversation is about NEUP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% +0

Jul 23

Neuphoria Therapeutics Inc. (NEUP) and Scancell Holdings plc (SCLP) have announced an all-share merger, where Scancell will acquire Neuphoria.
The combined company will operate as Scancell, advancing a pipeline of targeted, off-the-shelf, active immunotherapies, with Scancell shareholders owning approximately 85.5% and Neuphoria holders owning around 14.5%.
The deal comes with up to $89M in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+, and Neuphoria's shareholders may receive CVRs (convertible notes) in addition to the merger consideration.

Generated by AI

Sentiment

Of the messages about NEUP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0%	71.14% -14.25
Bearish	—	100%	100%	28.86% +14.25

Bullish· Oct 27

The company is likely to be sold, with a potential price range of $15 or higher, and a possible leak of takeover talks within 24 hours.
The company has taken measures to prevent a hostile takeover, including capping the current 37% holder and implementing poison pills, which could lead to a buyout.
The stock is expected to quadruple in value, with some investors already making significant profits, and the company's filing has confirmed the validity of bullish predictions.

Bearish· Oct 24

$NEUP's bid sizes significantly outweigh ask sizes, indicating a strong selling trend.
The company's recent $15M funding round may be a trap, as insiders are unlikely to sell shares and instead bought from the market.
$NEUP's price has dropped significantly from its daily highs, with a 6.30 average price point being a concerning level.

Generated by AI

Topics

Of the messages about NEUP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	13.84%
Technical Analysis	—	—	—	24.13%
Analysts	—	—	—	30.57%
Controversies	—	—	—	0.2%
Earnings	—	—	—	0%
Macro	—	—	—	31.25%

Jul 23

Scancell Holdings plc and Neuphoria Therapeutics Inc. have announced an all-share merger, with Scancell acquiring Neuphoria in an all-share transaction, and the combined company to operate under the name Scancell.
The merger deal includes up to $89 million in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+, and the combined company plans to apply for listing on the Nasdaq under the symbol "SCLT".
Under the terms of the merger, each outstanding share of Neuphoria common stock will be converted into 37.77199 Scancell American Depositary Shares (ADSs) and one Contingent Value Right (CVR), with Scancell shareholders owning approximately 85.5% of the combined entity.

Generated by AI

Community

Of the messages about NEUP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	50%	8.33%
Newcomers	—	100%	50%	91.67%

Regulars· Jul 23

The merger deal between Neuphoria Therapeutics Inc. and Scancell is expected to result in a post-dilution valuation of $239M, with Neuphoria receiving approximately 10% of the combined entity.
The current market capitalization of Scancell is estimated to be around $150M, and the pre-money valuation is around $160M, with Neuphoria's share valued at $4.30-4.40 per share.
The CVRs (contingent value rights) associated with the merger are expected to be worth a significant amount, with some estimates suggesting a value of $13 per share for Neuphoria, implying a total value of $511M for the combined entity.

Newcomers· Jul 23

The merger between Neuphoria Therapeutics Inc. ($NEUP) and Scancell Holdings plc ($SCLP) is an all-share transaction, with Scancell shareholders owning 85.5% of the combined entity.
The deal includes up to $89M in financing to fund a Phase 3 trial for Scancell's melanoma immunotherapy iSCIB1+, which will be the combined company's lead program.
The merger is expected to result in a significant increase in Neuphoria's share price, with some investors anticipating a target price of $4.00 or higher.

Generated by AI

Neuphoria Therapeutics

Social

Jul 23

Bullish· Oct 27

Bearish· Oct 24

Jul 23

Regulars· Jul 23

Newcomers· Jul 23

Neuphoria Therapeutics to Merge with Scancell Holdings

Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

Also Discussed

Neuphoria Therapeutics Inc.

Company Information

Location

Neuphoria Therapeutics to Merge with Scancell Holdings

Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

Also Discussed

Social

Jul 23

Bullish· Oct 27

Bearish· Oct 24

Jul 23

Regulars· Jul 23

Newcomers· Jul 23